MD
Pediatrix Medical Group, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $10 | $23 | +126% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $9.94 | $23 | +128% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $9.94 | $23 | +128% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $9.94 | $23 | +128% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $9.94 | $23 | +128% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q3 2024 | Q2 2026 | → $22 | +126% |
| Point72 Asset Management 2× in & out | Q3 2025 | Q1 2026 | → $22 | +40% |
| Bridgewater Associates 4× in & out | Q3 2021 | Q1 2025 | → $14 | -56% |
| Maverick Capital 3× in & out | Q2 2023 | Q3 2023 | → $15 | +2% |
| Coatue Management | Q1 2020 | Q2 2020 | → $13 | -50% |
| Elliott Management | Q1 2018 | Q2 2019 | → $28 | -48% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Pediatrix Medical Group, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-255710Jun 3, 2026
- Form 40001193125-26-255705Jun 3, 2026
- Form 40001193125-26-255704Jun 3, 2026
- Form 40001193125-26-255703Jun 3, 2026
- Form 40001193125-26-224280May 14, 2026
- Form 40001193125-26-224279May 14, 2026
- Form 40001193125-26-221884May 13, 2026
- Form 40001193125-26-217256May 11, 2026
- Form 40001193125-26-217253May 11, 2026
- Form 40001193125-26-217242May 11, 2026
- Form 40001193125-26-217235May 11, 2026
- Form 40001193125-26-217234May 11, 2026
- Form 40001193125-26-217227May 11, 2026
- Form 40001193125-26-217222May 11, 2026
- Form 40001193125-26-217219May 11, 2026
Fundamentals
XBRL · Pediatrix Medical Group, Inc.Annual figures sourced directly from Pediatrix Medical Group, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Pediatrix Medical Group, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 7, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 5, 2026
- DEF 14AProxy statementMar 27, 2026
- 10-KAnnual reportFeb 19, 2026
- 8-KMaterial eventFeb 19, 2026
- 10-QQuarterly reportNov 3, 2025
- 8-KMaterial eventNov 3, 2025
- 8-KMaterial eventAug 18, 2025
- 10-QQuarterly reportAug 5, 2025
- 8-KMaterial eventAug 5, 2025
- 8-KMaterial eventJul 1, 2025
- 8-KMaterial eventMay 8, 2025
- 10-QQuarterly reportMay 6, 2025
- 8-KMaterial eventMay 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q4 2025 | open | $23 | $23 | -2% |
| Point72 Asset Management | Q3 2025 | Q1 2026 | $16 | $22 | +40% |
| Citadel Advisors | Q3 2024 | open | $9.94 | $23 | +128% |
| Two Sigma Investments | Q3 2024 | Q3 2025 | $9.94 | $16 | +56% |
| D.E. Shaw | Q3 2024 | open | $9.94 | $23 | +128% |
| AQR Capital Management | Q3 2024 | open | $9.94 | $23 | +128% |
| Millennium Management | Q3 2024 | Q2 2026 | $9.94 | $22 | +126% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $9.94 | $15 | +48% |
| Renaissance Technologies | Q3 2024 | open | $10 | $23 | +126% |
| Maverick Capital | Q2 2023 | Q3 2023 | $14 | $15 | +2% |
| Maverick Capital | Q3 2021 | Q2 2022 | $33 | $18 | -44% |
| Bridgewater Associates | Q3 2021 | Q1 2025 | $33 | $14 | -56% |
| Maverick Capital | Q2 2020 | Q2 2021 | $13 | $32 | +136% |
| Coatue Management | Q1 2020 | Q2 2020 | $27 | $13 | -50% |
| Bridgewater Associates | Q2 2019 | Q3 2019 | $29 | $22 | -23% |
| Elliott Management | Q1 2018 | Q2 2019 | $55 | $28 | -48% |
| Bridgewater Associates | Q2 2016 | Q3 2016 | $69 | $65 | -6% |
| Bridgewater Associates | Q4 2015 | Q1 2016 | $70 | $65 | -6% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.